MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/bmj-2022-072175

Медицинская библиотека · BMJ (Clinical research ed.) · 2022

Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.

Jardine Meg J, Kotwal Sradha S, Bassi Abhinav, Hockham Carinna, Jones Mark, Wilcox Arlen, Pollock Carol, Burrell Louise M, McGree James, Rathore Vinay, Jenkins Christine R, Gupta Lalit, Ritchie Angus, Bangi Ashpak, D'Cruz Sanjay, McLachlan Andrew J, Finfer Simon, Cummins Michelle M, Snelling Thomas, Jha Vivekanand, CLARITY trial investigators

Adaptive Clinical TrialКлиническое исследование III фазыСтатьяМногоцентровое исследованиеPragmatic Clinical TrialРандомизированное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

To determine whether disrupting the renin angiotensin system with angiotensin receptor blockers will improve clinical outcomes in people with covid-19.

DESIGN

CLARITY was a pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.

SETTING

17 hospital sites in India and Australia.

PARTICIPANTS

Participants were at least 18 years old, previously untreated with angiotensin receptor blockers, with a laboratory confirmed diagnosis of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection who had been admitted to hospital for management of covid-19.

INTERVENTION: Oral angiotensin receptor blockers (telmisartan in India) or placebo (1:1) for 28 days.

MAIN OUTCOME MEASURES: The primary endpoint was covid-19 disease severity using a modified World Health Organization Clinical Progression Scale (WHO scale) at day 14. Secondary outcomes were WHO scale scores at day 28, mortality, intensive care unit admission, and respiratory failure. Analyses were evaluated on an ordinal scale in the intention-to-treat population.

RESULTS

Between 3 May 2020 and 13 November 2021, 2930 people were screened for eligibility, with 393 randomly assigned to angiotensin receptor blockers (of which 388 (98.7%) to telmisartan 40 mg/day) and 394 to the control group. 787 participants were randomised: 778 (98.9%) from India and nine (1.1%) from Australia. The median WHO scale score at day 14 was 1 (interquartile range 1-1) in 384 participants assigned angiotensin receptor blockers and 1 (1-1) in 382 participants assigned placebo (adjusted odds ratio 1.51 (95% credible interval 1.02 to 2.23), probability of an odds ratio of >1 (Pr(OR>1)=0.98). WHO scale scores at day 28 showed little evidence of difference between groups (1.02 (0.55 to 1.87), Pr(OR>1)=0.53). The trial was stopped when a prespecified futility rule was met.

CONCLUSIONS

In patients admitted to hospital for covid-19, mostly with mild disease, not requiring oxygen, no evidence of benefit, based on disease severity score, was found for treatment with angiotensin receptor blockers, using predominantly 40 mg/day of telmisartan.

TRIAL REGISTRATION: ClinicalTrials.gov NCT04394117.

Для цитирования: Jardine Meg J, Kotwal Sradha S, Bassi Abhinav, Hockham Carinna, Jones Mark, Wilcox Arlen, Pollock Carol, Burrell Louise M, McGree James, Rathore Vinay, Jenkins Christine R, Gupta Lalit, Ritchie Angus, Bangi Ashpak, D'Cruz Sanjay, McLachlan Andrew J, Finfer Simon, Cummins Michelle M, Snelling Thomas, Jha Vivekanand, CLARITY trial investigators. Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.. BMJ (Clinical research ed.). 2022. DOI: 10.1136/bmj-2022-072175.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.